Quantum-Si

Biotech tools / protein sequencingUSA
New to Unitard
πŸ“‰ Public < $1B
PeakΒ $1.46 BillionToday
βˆ’89%
from peak
  1. πŸ¦„
    Became a unicorn
    2021
  2. πŸ“ˆ
    Peak valuation
    $1.46 Billion ’21
  3. πŸ’”
    Became a Unitard
    2022
  4. πŸ’Έ
    Last valuation
    ~$169M
Current status
Public (Nasdaq: QSI)
Live Β· QSIΒ· NasdaqGM
as of 2026-09-17
$0.77β–² 4.19% today
β‰ˆΒ $169 Million market cap Β· βˆ’88.5% from peak

The rise & fall

5 moments Β· 2013–2024

The key moments, with employee sentiment along the way.

2013
Founded in Jonathan Rothberg's startup foundry
The DNA-sequencing pioneer's 4Catalyzer incubator sets out to do for proteins what cheap genome sequencing did for DNA.
GenomeWeb
Jun 2021
The peak: a $1.46B SPAC debut$1.46B
Merges with HighCape Capital's SPAC on the back of an oversubscribed $425M PIPE β€” with the chips still years from market.
GlobeNewswire
2022
Slips out of the club
Commercial traction comes slowly, and the pre-revenue premium evaporates as the market turns on biotech-tools SPACs.
GenomeWeb
From the inside Β· Glassdoor reviews, 2022–24
Glassdoor reviews across the slide counted repeated layoff rounds β€” unusually frequent for a company its size β€” with employees pointing to shifting priorities and abandoned projects, and describing a leadership team slow to set a clear direction.
Today
Still in the club β€” and still trading
Live Β· QSI Β· NasdaqGMas of 2026-09-17
$0.77β–² 4.19% todayβ‰ˆ $169M cap Β· βˆ’88.5% from peak

πŸ’¬ entries paraphrase anonymous, unverified reviews posted publicly on Glassdoor β†—; dated facts carry their source.

How it happened

Quantum-Si is developing semiconductor-chip-based 'next-generation protein sequencing,' aiming to do for proteins what cheap DNA sequencing did for genomics, and went public in June 2021 via a SPAC merger with HighCape Capital at a $1.46B valuation, backed by an oversubscribed $425M PIPE. Commercial traction came slowly and the market soured on pre-revenue biotech-tools SPACs; the stock fell about 88% to around $180M.

Source: GlobeNewswire / GenomeWeb / stockanalysis ($1.46B pro forma equity value via HighCape Capital SPAC, June 2021, ~$425M PIPE; ~$180M market cap by 2026)

Founder

  • Jonathan Rothberg
    Founder & Executive Chairman (interim CEO 2022); current CEO is Jeff Hawkins
    Still there β€” Founder and ChairmanLinkedIn β†—

Current roles as self-reported on LinkedIn, retrieved 2026-08-21. See our methodology.

More from the club

πŸ¦„